"As Alaska’s largest oncology practice, Katmai Oncology Group provides superior cancer treatment with a compassionate care philosophy. Katmai Oncology is the only QOPI certified oncology practice in Alaska, combined with our Seattle Cancer Care Alliance (SCCA) affiliation, Katmai Oncology Group is the #1 choice for cancer care in Alaska. Dr. Dale Webb, MD started the oncology practice in 1973 and was later named Katmai Oncology Group in 1996. Today, our staff is composed of the finest, most-highly qualified in Alaska. With 6 board-certified oncologists, 6 oncology-specialized ANPs, combined with infusion-certified nurses, and support staff to lend support and guidance on a range of integrative care specialties and services."

During the past decade, Katmai Oncology Group conducted 156 clinical trials. In the 10-year time frame, 156 clinical trials started and 71 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 63 clinical trials started and 59 clinical trials were completed. i.e. 93.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Katmai Oncology Group" #1 sponsor was "National Cancer Institute (NCI)" with 93 trials, followed by "Alliance for Clinical Trials in Oncology" with 37 trials sponsored, "SWOG Cancer Research Network" with 34 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 17 trials sponsored and "Gynecologic Oncology Group" with 17 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Katmai Oncology Group" #1 collaborator was "National Cancer Institute (NCI)" with 108 trials as a collaborator, "NRG Oncology" with 19 trials as a collaborator, "Canadian Cancer Trials Group" with 9 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator and "Astellas Pharma US, Inc." with 2 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 35 trials.

According to Clinical.Site data, the most researched conditions in "Katmai Oncology Group" are "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Invasive Breast Carcinoma" (8 trials), "Recurrent Ovarian Carcinoma" (7 trials), "Stage IV Lung Cancer AJCC v8" (7 trials) and "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials). Many other conditions were trialed in "Katmai Oncology Group" in a lesser frequency.

Most popular intervention types in "Katmai Oncology Group" are "Drug" (168 trials), "Other" (121 trials), "Biological" (89 trials), "Procedure" (58 trials) and "Radiation" (28 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (60 trials), "Quality-of-Life Assessment" (50 trials), "Computed Tomography" (33 trials), "Biospecimen Collection" (30 trials) and "Questionnaire Administration" (29 trials). Other intervention names were less common.

The vast majority of trials in "Katmai Oncology Group" are 171 trials for "All" genders, 31 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Katmai Oncology Group". undefined are not yet recruiting, 62 are recruiting, 99 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Katmai Oncology Group, 5 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Katmai Oncology Group, 7 "Phase 1" clinical trials were conducted, 109 "Phase 2" clinical trials and 100 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".